Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin Delayed Release (400 mg Tablet) for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. A Phase II, Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial

NCT03469050 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.

NCT NCT03469050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03469050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin Delayed Release (400 mg Tablet) for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. A Phase II, Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial
Lead sponsor
Alfasigma S.p.A.
Phase
Phase 2/3
Overall status
Terminated
Start date
July 2, 2018
Completion date
December 22, 2020
Enrollment
193 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

diverticulitis